This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Monopar Therapeutics’s 8K filing here.
Monopar Therapeutics Company Profile
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
- Five stocks we like better than Monopar Therapeutics
- How to Invest in the FAANG Stocks
- The Top 5 Performing S&P 500 Stocks YTD in 2024
- What Do S&P 500 Stocks Tell Investors About the Market?
- L3Harris: Positioned for Gains With Trump’s Defense Policies
- How to Calculate Inflation Rate
- Is First Solar’s Earnings Drop a Golden Buying Opportunity?
